What is Psoriasis?

Psoriasis is a chronic, immune-mediated inflammatory disease affecting approximately 2-3% of the population. It is characterized by accelerated keratinocyte proliferation, abnormal differentiation, and inflammatory infiltrate, resulting in erythematous (red), scaly plaques. The disease typically manifests with a cyclical pattern of exacerbations and remissions, though some patients experience chronic progression. Psoriasis profoundly impacts quality of life, affecting skin, joints, nails, and systemic health.

Epidemiology and Risk Factors

Psoriasis affects approximately 125 million individuals worldwide. Peak incidence occurs in the third and fourth decades of life, though disease can manifest at any age, including childhood. Genetic predisposition is strong, with concordance rates of 70% in monozygotic twins. Environmental triggers including infections (particularly streptococcal pharyngitis), stress, medications, and trauma activate disease in genetically susceptible individuals. HLA-Cw6 positivity correlates with earlier disease onset and more severe phenotypes.

Disease Mechanism

Psoriasis involves dysregulation of innate and adaptive immune responses. Genetic polymorphisms in genes regulating T-cell function and toll-like receptor signaling predispose to disease. Environmental triggers activate dendritic cells and innate lymphoid cells, initiating T-helper 17 (Th17) and tumor necrosis factor-alpha (TNF-alpha) pathways. This drives excessive keratinocyte proliferation, impaired differentiation, and formation of characteristic histological findings including parakeratosis (retained nuclei in stratum corneum) and elongation of rete ridges. The cycle perpetuates with additional immune infiltration and epidermal barrier dysfunction.

Types of Psoriasis

Plaque Psoriasis

The most common subtype, affecting 85-90% of patients. Characterized by well-demarcated erythematous plaques with silvery scales, typically symmetric distribution on extensor surfaces (elbows, knees), scalp, and trunk. Lesions are often pruritic or painful.

Guttate Psoriasis

Presents with numerous small (1-10mm) lesions often following streptococcal infection. Typically acute onset and may resolve spontaneously. More common in children and young adults.

Inverse Psoriasis

Affects intertriginous areas (skin folds) including axillae, groin, and under breasts. Lesions lack the typical scale due to moisture and friction. Often more difficult to treat due to location and potential for maceration.

Pustular Psoriasis

Characterized by sterile pustules on erythematous background. Localized form involves palms and soles; generalized form is rare but potentially life-threatening, requiring hospitalization for fluid and electrolyte management.

Erythrodermic Psoriasis

Involves >80% body surface area with systemic inflammation. Represents dermatological emergency requiring hospitalization for temperature regulation and fluid balance management.

Common Triggers

Infections: Streptococcal pharyngitis is the most common infectious trigger, particularly for guttate psoriasis. Other pathogens including Staphylococcus aureus and viral infections may trigger exacerbations.

Trauma: Psoriasis exhibits Koebner phenomenon, where new lesions develop at sites of physical trauma, scratching, or surgical wounds, sometimes with 7-14 day lag.

Medications: Beta-blockers, lithium, NSAIDs, and rapid corticosteroid withdrawal can exacerbate disease.

Psychological Stress: Emotional stress triggers or exacerbates psoriasis in 40-60% of patients through neuroimmune mechanisms.

Climate: Many patients note worsening in winter and improvement with sun exposure (phototherapy effect).

Diagnosis

Diagnosis is primarily clinical, based on characteristic morphology and distribution. Dermoscopy may reveal vascular patterns including regular distribution of dots and globules. Histopathology shows parakeratosis, elongated rete ridges, capillary dilation in dermal papillae, and inflammatory infiltrate. Biopsy is performed if diagnosis is unclear or to differentiate from other conditions. Systemic assessment should include evaluation for joint involvement (psoriatic arthritis) and cardiovascular risk factors.

Expert Tip

Screen all patients with psoriasis for psoriatic arthritis through clinical history and examination. Approximately 30% of patients develop joint involvement, sometimes before skin manifestations. Early identification enables better disease management and prevents irreversible joint damage.

Treatment Approaches

Topical Treatments

Corticosteroids are first-line topical agents, with potency selected based on location and severity. Potent agents are appropriate for body involvement; lower potency agents for face and intertriginous areas to avoid atrophy. Calcineurin Inhibitors (tacrolimus, pimecrolimus) are steroid-sparing alternatives particularly useful for facial and intertriginous involvement. Vitamin D Analogues (calcipotriene) normalize keratinocyte differentiation. Coal Tar, though older, remains effective and non-systemic. Salicylic Acid aids scale removal.

Phototherapy

Narrow-Band UVB (NB-UVB) remains gold-standard phototherapy, with 75% of patients achieving >75% improvement with twice-weekly treatments. PUVA (psoralen plus UVA) provides alternative for patients not responding to NB-UVB. Excimer Laser targets localized plaques with high-intensity UVB. Phototherapy is safe for children and pregnant women and can be combined with topical or systemic agents.

Systemic Treatments

Methotrexate is a conventional systemic agent effective for moderate-to-severe disease and psoriatic arthritis. Requires regular monitoring of liver and kidney function. Acitretin is an oral retinoid effective particularly for pustular psoriasis. Cyclosporine provides rapid improvement suitable for acute flares or severe disease.

Biologic Therapies: TNF-alpha inhibitors (infliximab, etanercept, adalimumab) are highly effective. IL-17 inhibitors (secukinumab, ixekizumab) show excellent efficacy for plaque psoriasis. IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) provide sustained remission with favorable safety profiles. JAK inhibitors represent emerging oral options.

Associated Conditions

Psoriasis is associated with multiple comorbidities requiring screening and management: psoriatic arthritis (30%), metabolic syndrome (40%), cardiovascular disease (30-40% increased risk), obesity, diabetes, depression, and anxiety. Systemic inflammation and shared genetic factors contribute to these associations. Comprehensive patient care addresses these comorbidities.

Lifestyle Management

  • Identify and avoid personal triggers through symptom tracking
  • Manage stress through counseling, meditation, or stress-reduction programs
  • Maintain good skin hygiene with lukewarm water and gentle cleansers
  • Use emollients extensively to maintain skin barrier function
  • Moderate sun exposure; controlled phototherapy is beneficial
  • Maintain healthy weight and address metabolic comorbidities
  • Avoid smoking and excessive alcohol
  • Consider support groups for psychological well-being